Vasoactive Peptides with Angiogenesis-Regulating Activity Predict Cancer Risk in Males.
(2012) In Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 21(3). p.513-522- Abstract
- BACKGROUND: Tumor development requires angiogenesis, and antiangiogenesis has been introduced in the treatment of cancer patients; however, how the cardiovascular phenotype correlates with cancer risk remains ill-defined. Here, we hypothesized that vasoactive peptides previously implicated in angiogenesis regulation predict long-term cancer risk.METHODS: We measured midregional proatrial natriuretic peptide (MR-proANP), proadrenomedullin (MR-proADM), and C-terminal preprovasopressin (copeptin) in fasting plasma from participants of the Malmö Diet and Cancer Study that were free from cancer prior to the baseline exam in 1991 to 1994 (1,768 males and 2,293 females). We used Cox proportional hazards models to determine the time to first... (More)
- BACKGROUND: Tumor development requires angiogenesis, and antiangiogenesis has been introduced in the treatment of cancer patients; however, how the cardiovascular phenotype correlates with cancer risk remains ill-defined. Here, we hypothesized that vasoactive peptides previously implicated in angiogenesis regulation predict long-term cancer risk.METHODS: We measured midregional proatrial natriuretic peptide (MR-proANP), proadrenomedullin (MR-proADM), and C-terminal preprovasopressin (copeptin) in fasting plasma from participants of the Malmö Diet and Cancer Study that were free from cancer prior to the baseline exam in 1991 to 1994 (1,768 males and 2,293 females). We used Cox proportional hazards models to determine the time to first cancer event in relation to baseline levels of vasoactive peptides during a median follow-up of 15 years.RESULTS: First cancer events occurred in 366 males and in 368 females. In males, one SD increase of MR-proANP, copeptin, and MR-proADM was independently related to incident cancer [HR (95% CI)] by 0.85 (0.74-0.96), P = 0.012; 1.17 (1.04-1.32), P = 0.009; and 1.12 (0.99-1.26), P = 0.065, respectively, and a summed biomarker score identified an almost 2-fold difference in cancer risk between the top and bottom quartile (P < 0.001). In younger males, the biomarker score identified a more than 3-fold increase in risk between the top and bottom quartile (P < 0.001). Among females, we found no relationship between biomarkers and cancer incidence.CONCLUSIONS: Our data suggest that vasoactive peptide biomarkers predict cancer risk in males, particularly in younger males.Impact: Our findings may have implications for cancer risk prediction and present novel, potentially drug modifiable, mechanisms underlying cancer development. Cancer Epidemiol Biomarkers Prev; 1-10. ©2012 AACR. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/2336090
- author
- Belting, Mattias LU ; Almgren, Peter LU ; Manjer, Jonas LU ; Hedblad, Bo LU ; Struck, Joachim ; Wang, Thomas J ; Bergmann, Andreas and Melander, Olle LU
- organization
-
- Breastcancer-genetics
- Translational Muscle Research (research group)
- Surgery (research group)
- Cardiovascular Research - Epidemiology (research group)
- Cardiovascular Research - Hypertension (research group)
- EXODIAB: Excellence of Diabetes Research in Sweden
- EpiHealth: Epidemiology for Health
- BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
- volume
- 21
- issue
- 3
- pages
- 513 - 522
- publisher
- American Association for Cancer Research
- external identifiers
-
- wos:000301284100016
- pmid:22267286
- scopus:84859402298
- pmid:22267286
- ISSN
- 1538-7755
- DOI
- 10.1158/1055-9965.EPI-11-0840
- language
- English
- LU publication?
- yes
- id
- 542cef48-70e6-4511-afe6-36abecab55ee (old id 2336090)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/22267286?dopt=Abstract
- date added to LUP
- 2016-04-04 09:44:40
- date last changed
- 2024-05-11 13:20:13
@article{542cef48-70e6-4511-afe6-36abecab55ee, abstract = {{BACKGROUND: Tumor development requires angiogenesis, and antiangiogenesis has been introduced in the treatment of cancer patients; however, how the cardiovascular phenotype correlates with cancer risk remains ill-defined. Here, we hypothesized that vasoactive peptides previously implicated in angiogenesis regulation predict long-term cancer risk.METHODS: We measured midregional proatrial natriuretic peptide (MR-proANP), proadrenomedullin (MR-proADM), and C-terminal preprovasopressin (copeptin) in fasting plasma from participants of the Malmö Diet and Cancer Study that were free from cancer prior to the baseline exam in 1991 to 1994 (1,768 males and 2,293 females). We used Cox proportional hazards models to determine the time to first cancer event in relation to baseline levels of vasoactive peptides during a median follow-up of 15 years.RESULTS: First cancer events occurred in 366 males and in 368 females. In males, one SD increase of MR-proANP, copeptin, and MR-proADM was independently related to incident cancer [HR (95% CI)] by 0.85 (0.74-0.96), P = 0.012; 1.17 (1.04-1.32), P = 0.009; and 1.12 (0.99-1.26), P = 0.065, respectively, and a summed biomarker score identified an almost 2-fold difference in cancer risk between the top and bottom quartile (P < 0.001). In younger males, the biomarker score identified a more than 3-fold increase in risk between the top and bottom quartile (P < 0.001). Among females, we found no relationship between biomarkers and cancer incidence.CONCLUSIONS: Our data suggest that vasoactive peptide biomarkers predict cancer risk in males, particularly in younger males.Impact: Our findings may have implications for cancer risk prediction and present novel, potentially drug modifiable, mechanisms underlying cancer development. Cancer Epidemiol Biomarkers Prev; 1-10. ©2012 AACR.}}, author = {{Belting, Mattias and Almgren, Peter and Manjer, Jonas and Hedblad, Bo and Struck, Joachim and Wang, Thomas J and Bergmann, Andreas and Melander, Olle}}, issn = {{1538-7755}}, language = {{eng}}, number = {{3}}, pages = {{513--522}}, publisher = {{American Association for Cancer Research}}, series = {{Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology}}, title = {{Vasoactive Peptides with Angiogenesis-Regulating Activity Predict Cancer Risk in Males.}}, url = {{http://dx.doi.org/10.1158/1055-9965.EPI-11-0840}}, doi = {{10.1158/1055-9965.EPI-11-0840}}, volume = {{21}}, year = {{2012}}, }